Marinus Pharma (MRNS) – Globe Newswire
-
Marinus Pharmaceuticals Provides Pipeline Update
-
Marinus Pharmaceuticals to Host Pipeline Update Webinar
-
Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary
-
Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
-
Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020
-
MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
-
Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications
-
Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results
-
Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder
-
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting
-
Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting
-
Marinus Provides Business Outlook for 2020
-
Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Share
-
Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors
-
Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
-
Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
-
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
-
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex
-
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
-
Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results
-
Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer
-
Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
Back to MRNS Stock Lookup
